Cystic Fibrosis Therapeutics Market Size, Share, and Growth Analysis, By Drug Class (CFTR Modulators, Pancreatic Enzyme Supplements), By Route Of Administration (Oral, Inhaled), By Distribution Channel, By Region - Industry Forecast 2025-2032
낭포성섬유증 치료제 시장 규모는 2023년 65억 달러로 평가되며, 2024년 74억 2,000만 달러에서 2032년 213억 1,000만 달러로 예측 기간(2025-2032년) 동안 14.1%의 CAGR로 성장할 것으로 예상됩니다.
낭포성섬유증(CF) 치료제 시장은 CF 유병률 증가와 치료율 증가에 힘입어 크게 성장할 것으로 예상됩니다. 공공 및 민간 부문의 연구 개발 자금 지원 강화와 강력한 비영리 이니셔티브가 시장 확대를 더욱 촉진하고 있습니다. 환자 수가 매년 증가함에 따라 CFTR 조절제, 점액 용해제, 항생제 등 기존 약물의 사용이 증가하고 있어 효과적인 치료법에 대한 수요가 증가하고 있습니다. 또한, 주요 제약회사들의 혁신적인 치료제 파이프라인의 증가와 고객층 확대를 위한 연구 진행도 시장 역학에 기여하고 있으며, CF 연구 개발을 지원하는 여러 자선단체의 적극적인 역할도 시장 성장을 촉진하는 중요한 요소입니다.
목차
소개
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장 가정과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porters 분석
주요 시장 인사이트
- 핵심성공요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 규제 분석
- 기술 분석
낭포성섬유증 치료제 시장 규모 : 약물 종류별 & CAGR(2025-2032년)
- 시장 개요
- 항감염제
- CFTR 모듈레이터
- 췌장 효소 보충제
- 점액용해제
- 기관지확장제
낭포성섬유증 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032년)
낭포성섬유증 치료제 시장 규모 : 유통 채널별 & CAGR(2025-2032년)
낭포성섬유증 치료제 시장 규모 : 지역별 & CAGR(2025-2032년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5개사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채용한 전략
- 최근의 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 상세
- 제품 포트폴리오 분석
- 기업 부문별 점유율 분석
- 매출 전년비 비교(2022-2024년)
주요 기업 개요
- Vertex Pharmaceuticals(USA)
- AbbVie(USA)
- Gilead Sciences(USA)
- Roche(Switzerland)
- Teva Pharmaceutical Industries(Israel)
- Mylan(now Viatris)(USA)
- Novartis AG(Switzerland)
- AstraZeneca(UK)
- Alaxia.
- Allergan(now part of AbbVie)(Ireland)
- Beyond Air Inc.(USA)
- F. Hoffmann-La Roche Ltd.(Switzerland)
- Merck & Co. Inc.(USA)
- Alcresta Therapeutics Inc.(USA)
- Chiesi(Italy)
- Nestle HealthScience(Switzerland)
- Pharmaxis Ltd.(Australia)
- PTC Therapeutics, Inc.(USA)
- Insmed, Inc.(USA)
- Grifols S.A.(Spain)
결론과 제안
ksm
Cystic Fibrosis Therapeutics Market size was valued at USD 6.5 billion in 2023 and is poised to grow from USD 7.42 billion in 2024 to USD 21.31 billion by 2032, growing at a CAGR of 14.1% during the forecast period (2025-2032).
The cystic fibrosis (CF) therapeutics market is poised for significant growth driven by the rising prevalence of CF and an increase in treatment rates. Enhanced funding for research and development from both public and private sectors, along with robust nonprofit initiatives, is further propelling market expansion. The demand for effective therapies is increasing due to a year-on-year rise in patient numbers, leading to greater utilization of existing drug classes, including CFTR modulators, mucolytics, and antibiotics. Additionally, a growing pipeline of innovative therapy compositions from leading pharmaceutical companies and ongoing studies aimed at broadening their customer base will contribute to market dynamics. The active role of several charitable organizations in supporting CF research and development is also a crucial factor in fostering market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Cystic Fibrosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Cystic Fibrosis Therapeutics Market Segments Analysis
Global Cystic Fibrosis Therapeutics Market is segmented by Drug Class, Route Of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-infectives, CFTR Modulators, PancreaticenzymeSupplements, Mucolytics and Bronchodilators. Based on Route Of Administration, the market is segmented into Oral and Inhaled. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Cystic Fibrosis Therapeutics Market
The cystic fibrosis therapeutics market is predominantly driven by the rising incidence of cystic fibrosis, a genetic disorder that significantly impacts the respiratory, digestive, and reproductive systems. As this debilitating condition remains incurable, patients necessitate continuous treatment throughout their lives, which in turn fuels the demand for effective cystic fibrosis therapeutics. As more individuals are diagnosed and require ongoing care, the market is expected to see substantial growth, underscoring the critical need for innovative treatments and supportive therapies to enhance the quality of life for those affected by this chronic illness.
Restraints in the Cystic Fibrosis Therapeutics Market
The elevated prices associated with cystic fibrosis treatments, especially innovative targeted therapies, pose a significant challenge to patient access. This situation raises crucial concerns regarding the affordability of these essential medications and their influence on healthcare systems. Many patients are unable to obtain necessary treatments due to the financial burden, which can lead to potential disparities in healthcare outcomes. As a result, these high costs not only affect individual patients but also strain the resources of healthcare providers and insurers, ultimately complicating the management of cystic fibrosis and limiting the overall efficacy of available therapies.
Market Trends of the Cystic Fibrosis Therapeutics Market
The cystic fibrosis therapeutics market is witnessing a significant shift towards personalized medicine, driven by advancements in genomic research and a deeper understanding of the disease's genetic underpinnings. As more targeted therapies emerge that cater to specific mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, patients are increasingly seeking tailored treatment options that provide enhanced efficacy and improved outcomes. This trend is anticipated to escalate, encouraging pharmaceutical companies to invest in innovative research and development, ultimately transforming cystic fibrosis management. Consequently, a robust growth trajectory is expected in the personalized medicines segment, solidifying its prominence in the evolving therapeutics landscape.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Analysis
- Technology Analysis
Global Cystic Fibrosis Therapeutics Market Size by Drug Class & CAGR (2025-2032)
- Market Overview
- Anti-infectives
- CFTR Modulators
- Pancreatic Enzyme Supplements
- Mucolytics
- Bronchodilators
Global Cystic Fibrosis Therapeutics Market Size by Route Of Administration & CAGR (2025-2032)
- Market Overview
- Oral
- Inhaled
Global Cystic Fibrosis Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Cystic Fibrosis Therapeutics Market Size & CAGR (2025-2032)
- North America (Drug Class, Route Of Administration, Distribution Channel)
- Europe (Drug Class, Route Of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Route Of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Route Of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Route Of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Vertex Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan (now Viatris) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alaxia.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan (now part of AbbVie) (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Beyond Air Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcresta Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chiesi (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nestle HealthScience (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharmaxis Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PTC Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Insmed, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
